PharmNovo further strengthens the organisation
The Swedish pharmaceutical company PharmNovo AB, which is developing a new type of drug for neuropathic pain, announces that the team has been further strengthened in connection with the company now taking the step from preclinical to clinical development.
PharmNovo has strengthened the team with a new experienced Project Manager and a Clinical Trial Manager to continue the development of the company's drug candidate PN6047 for the treatment of neuropathic pain, so-called nerve pain.
Inge Tarnow joins the team as the new Senior Project Manager and will lead and coordinate the work with PN6047. Inge Tarnow holds a Ph.D. in pathophysiology and is a Doctor of Veterinary Medicine. She has worked as a project manager at Savara, a biopharmaceutical company focusing on rare respiratory diseases, for six years.
"We are pleased to welcome Inge Tarnow. Her experience in clinical and non-clinical drug development and regulatory interactions will benefit PharmNovo advancing PN6047 through the clinical phase," says Per von Mentzer, CEO of PharmNovo.
PharmNovo also welcomes Thomas Eskildsen, Senior Clinical Trial Manager. He will oversee the phase I study while being an asset to the team in the planning and managing future phase IIa studies.
"Thomas has solid experience in delivering, coordinating, and managing all activities related to clinical trials, from start-up to operational implementation and compilation. Thomas will also be a great contribution to the team and the development of PN6047 in the future," says Per von Mentzer.
During the summer, PharmNovo appointed Tommy Nilsson as CFO and Jarkko Kalliomäki as Clinical Lead and CMO. Read more about them in a previous press release.
For more information, please contact:
Per von Mentzer, CEO
Phone +46 705 44 32 50
Email: per.von.mentzer@pharmnovo.com
About PharmNovo
PharmNovo AB is a clinical phase pharmaceutical company focused on developing safe and effective drugs for neuropathic pain. In this area, there is currently a lack of sufficient treatment. The company's drug candidate, PN6047, has effectively reduced nerve pain in animal models in preclinical studies. The company also sees clinical potential in other areas such as migraine, anxiety/depression, and chronic cough. PharmNovo, headquartered in Medicon Village in Lund, Sweden, was founded in 2008 by Dr Bengt von Mentzer, who has more than 30 years of experience in drug development and pain research at Astra Zeneca. The team comprises prominent researchers in academia and industry, and the company has an extensive international network of leading expert advisors. To learn more, visit pharmnovo.com.
Tags:
